Immunological Variables Associated With Clinical and Endoscopic Response to Vedolizumab in Patients With Inflammatory Bowel Diseases

Fantini, Massimo Claudio;Vecchi, Maurizio;
2020-01-01

Abstract

Vedolizumab [VDZ] is a monoclonal antibody directed against the α4β7 integrin heterodimer, approved for patients with inflammatory bowel diseases [IBD]. This study aimed at identifying immunological variables associated with response to vedolizumab in patients with ulcerative colitis [UC] and Crohn's disease [CD].
2020
Inglese
JOURNAL OF CROHN'S AND COLITIS
14
9
1190
1201
12
WOS:000582308300004
2-s2.0-85091126855
32100016
Esperti anonimi
internazionale
scientifica
IBD; T cell subsets; Vedolizumab
no
Coletta, Marina; Paroni, Moira; Alvisi, Maria Francesca; De Luca, Matilde; Rulli, Eliana; Mazza, Stefano; Facciotti, Federica; Lattanzi, Georgia; Stra ...espandi
1.1 Articolo in rivista
info:eu-repo/semantics/article
1 Contributo su Rivista::1.1 Articolo in rivista
262
14
reserved
Files in This Item:
File Size Format  
Coletta M et al J Crohns Colitis 2020.pdf

Solo gestori archivio

Type: versione editoriale
Size 3.56 MB
Format Adobe PDF
& nbsp; View / Open   Request a copy
3.56 MB Adobe PDF & nbsp; View / Open   Request a copy

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Questionnaire and social

Share on:
Impostazioni cookie